Erenumab
Based on 1 publication(s) in Google Scholar
Erenumab (AMG-334) is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.88%
- CAS No.: 1582205-90-0
- Masse moléculaire:145.5 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Erenumab
More
Activité biologique
Human IgG2 lambda
Human
CALCRL/CGRPR
Erenumab (1-100 nM) competitively inhibits the vasodilatory effect induced by aCGRP, with a pA2 of 9.00 in cerebral arteries and an apparent pKB of 7.50 in meningeal arteries, indicating that it is more potent in cerebral arteries[2].
Erenumab (0.5 pM-10 μM, 3 h) competes with [125I]-CGRP for binding to human CGRP receptors, with a Ki value of 0.02 nM. In cell-based functional assays (human CGRP receptors), AMG 334 fully inhibits CGRP-stimulated cyclic adenosine monophosphate (cAMP) production, with an IC50 of 2.3 nM[3].
Erenumab (0.5 pM-10 μM, 3 h) exhibits antagonistic potency at cynomolgus monkey CGRP receptors, with an IC50 of 5.7 nM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynos[1]
-
Dosage:0.1, 0.3, 3,
10, and 30 mg/kg -
Administration:i.v., single
-
Result:Dose
dependently prevented capsaicin-induced increases in dermal blood flow (DBF).
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 lambda
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1582205-90-0
-
Appearance Liquid
-
Masse moléculaire 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Erenumab]
-
Synonyms
AMG-334
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Mimotopes of calcitonin gene-related peptide (CGRP) screened from Fv-antibody library: antagonists to CGRP receptor. [Abstract]2025 Dec;334(Pt 2):149080. PMID: 41253226
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Shi L, et al. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther. 2016 Jan;356(1):223-31. [Content Brief]
[2]. Reuter U, et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108-118. [Content Brief]
[3]. Ohlsson L, et al. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. Cephalalgia. 2019;39(14):1745-1752. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Erenumab Related Classifications
HY-P9938 Related Classifications
Powered by Bioz